Skip to main content

Advertisement

Table 3 Number of patients reporting <2, ≥2, ≥6, or ≥10 inhalations/day in the week preceding the 2-month visit by treatment group

From: Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease

Mean reliever use (inhalations/day) BUD/FORM (n = 349) FORM (n = 325) P valuea
Patients with cut-point inhalations/day, n (%)
<2 114 (32.7) 79 (24.3) 0.017
≥2 235 (67.3) 246 (75.7) 0.017
≥6 111 (31.8) 136 (41.8) 0.007
≥10 27 (7.7) 65 (20.0) <0.001
  1. Patient n values are cumulative (i.e. all patients in the ≥10 group are also in the ≥2 and ≥6 groups) and represent the number of patients remaining in the analysis for the week before the 2-month visit
  2. BUD budesonide, FORM formoterol
  3. aP-values are for the analysis of BUD/FORM versus FORM